I started keeping this reverse timeline and abbreviated bibliography for my reporting on aducanumab and decided to post it online. Feel free to tweet at me at @Kdooleyyoung to recommend entries and articles I should include on this list.
2021
2021-Aug. 5. ICER issues final report on aducanumab. (Cut Aducanumab Cost, Speed Confirmatory Research, ICER Says Medscape Medical News.)
2021-Aug. 4 OIG announces review of FDA accelerated review process. (FDA’s Accelerated Drug Approval Process Under Investigation by OIG, Aug. 5, 2021. Medscape Medical News.)
2021-July 15 ICER panel finds no net benefit to aducanumab (No Net Benefit of Aducanumab for Alzheimer’s Disease, Expert Panel Rules, July 16, 2021. Medscape Medical News.)
2021-July 12. CMS announces national coverage analysis for aducanumab. ( Contentious Alzheimer’s Drug Likely to Get National Coverage Plan, CMS Says, July 13, 2021. Medscape Medical News. )
2021-June 7. FDA approves aducanumab
2020
2020-Nov. 6. FDA advisors essentially voted against approval of this drug. (FDA transcript of meeting)
2019
2019-March 21- Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
Bibliography
Books
Karlawish, Jason, “The Problem of Alzheimer’s: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It,” St. Martins Press, 2021
O’Brien, Greg, “On Pluto: Inside the Mind of Alzheimer’s,” Codfish Press, 2014